A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer

doi:10.1007/s00384-011-1377-3

CNU IR > College of Sustainable Environment and Recreation > Dept. of Sports Management > Periodical Articles > Item 310902800/27640

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/27640

Title:	A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer
Authors:	Chen, Chin-Fan Huang, Ming-Yii Huang, Chih-Jen Wu, Chan-Han Yeh, Yung-Sung Tsai, Hsiang-Lin Ma, Cheng-Jen Lu, Chien-Yu Chang, Shun-Jen Chen, Ming-Jenn Wang, Jaw-Yuan
Contributors:	運動管理系
Keywords:	Preoperative Chemoradiation Rectal Cancer Capecitabine 5-Fu
Date:	2012-06
Issue Date:	2014-03-21 16:16:09 (UTC+8)
Publisher:	Springer
Abstract:	This study is to evaluate the safety and efficacy of preoperative radiotherapy (RT) combined with bolus infusional 5-fluorouracil (5-FU) or oral capecitabine in patients with locally advanced rectal cancer (LARC).Seventy-four patients were retrospectively analyzed. Twenty-seven patients were treated with 5-FU (350 mg/m(2) IV bolus) and leucovorin (20 mg/m(2) IV bolus) for 5 days/week during week 1 and 5 of RT. Forty-seven patients were treated with capecitabine (850 mg/m(2), twice daily for 5 days/week). Both groups received the same RT course (45-50.4 Gy/25 fractions, 5 days/week, for 5 weeks). Patients underwent surgery in 6 weeks after completion of the chemoradiotherapy. Data of the observational study were collected.Grade 3 or 4 toxicities occurred in 40.7% (5-FU) and 19.1% (capecitabine) of the patients (P = 0.044). Six patients in the 5-FU group (22.2%) and six patients in the capecitabine group (14%) achieved complete response. Primary tumor (T) downstaging were achieved in 51.9% (5-FU) and 69.8% (capecitabine) of the patients. The pathological ypT0-2 stage was 40.7% (5-FU) and 67.4% (capecitabine) (P = 0.028).In consideration of the better ypT0-2 downstaging rate, less severe toxicities, and no need for indwelling intravenous device on oral capecitabine regimen, the administration of oral capecitabine with RT may be a more favorable option in the neoadjuvant treatment for LARC.
Relation:	International Journal of Colorectal Disease, 27(6), 727-736
Appears in Collections:	[Dept. of Sports Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1587	View/Open

Loading...